Effectiveness and safety of triple antiagregation in patients undergoing coronary intervention;Efectividad y seguridad de la «triple antiagregación» en pacientes sometidos a intervencionismo coronario

Medicina Intensiva

Volumn 31, Issue 5, 2007, Pages 220-230

  Latour Perez J ^a   De Miguel Balsa, E ^a   Alcala Lopez A ^a   Coves Orts, F J ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

Author keywords

Abciximab; Clopidogrel; Coronary angioplasty; Eptifibatide; IIb IIIa antagonists; Myocardial ischemia; non ST segment elevation acute coronary syndrome; Percutaneous revascularization; Survival; Thienopyridines; Ticlopidine; Tirofiban

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; PYRIDINE DERIVATIVE; TICLOPIDINE; TIROFIBAN;

ACUTE CORONARY SYNDROME; ARTICLE; BLEEDING; CARDIOVASCULAR RISK; COCHRANE LIBRARY; CONFIDENCE INTERVAL; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG SAFETY; EMBASE; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INFORMATION PROCESSING; MEDLINE; METHODOLOGY; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZATION; RISK ASSESSMENT; ST SEGMENT ELEVATION; SURVIVAL; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 34547639347     PISSN: 02105691     EISSN: 15786749     Source Type: Journal    
DOI: 10.1016/S0210-5691(07)74814-3     Document Type: Article

References (21)

1. Bertrand ME, Simoons ML, Fox KAA, Wallentin LC, Hamm CW, McFadden E, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J. 2002;23:1809-40.
2. Bosch X, Marrugat J. Platelet glycoprotein IIb/IIIa blockers for percutaneous coronary revascularization, and unstable angina and non-ST-segment elevation myocardial infarction. Cochrane Database Syst Rev. 2001:CD002130.
3. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman J, et al. ACC/AHA guidelines update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction - 2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation. 2002;106:1893-900.
4. Silber S, Albertsson P, Aviles FF, Camici PG, Colombo A, Hamm C, et al. Guidelines for percutaneous coronary interventions: The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J. 2005;26:804-47.
5. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-60.
6. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
7. Sterne JAC, Egger M, Smith GD. Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis. BMJ. 2001;323:101-5.
8. Bonz AW, Legenfelder B, Strotmann J, Held S, Turschner O, Harre K, et al. Effect of Additional Temporary Glycoprotein IIb/IIIa Receptor Inhibition on Troponin Release in Elective Percutaneous Coronary Interventions After Pretreatment with Aspirin and Clopidogrel (TOPSTAR trial). J Am Coll Cardiol. 2002;40:662-8.
9. The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial. Lancet. 2000;356:2037-44.
10. Claeys MJ, Van der Planken MG, Bosmans JM, Michiels JJ, Vertessen F, Van Der Goten P, et al. Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis. Eur Heart J. 2005;26:567-75.
11. Kastrati A, Mehilli J, Schühlen H, Dirschinger J, Dotzer F, ten Berg JM, et al. A Clinical Trial of Abciximab in Elective Percutaneous Coronary Intervention after Pretreatment with Clopidogrel. N Engl J Med. 2004;350:232-8.
12. Leoncini M, Toso A, Maioli M, Bellandi F, Badia T, Politi A, et al. Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non-ST-elevation acute coronary syndromes treated with early aggressive approach. Results of the CLOpidogrel, upstream TIrofiban, in cath Lab Downstream Abciximab (CLOTILDA) study. Am Heart J. 2005;150:401e9-401e14.
13. Mehilli J, Kastrati A, Schühlen H, Dibra A, Dotzer F, Von Beckerath N, et al. Randomized Clinical Trial of Abciximab in Diabetic Patients Undergoing Elective Percutaneous Coronary Interventions after Treatment with a High Loading Dose of Clopidogrel. Circulation. 2004;110:3627-35.
14. Okmen E, Sanli A, Tartan Z, Uyarel H, Kasikcioglu H, Cam N. Long-term follow-up after angiographically successful coronary stenting: direct stent versus conventional stent implantation. Jpn Heart J. 2004;45:53-62.
15. Steinhubl SR, Ellis SG, Wolski K, Lincoff AM, Topol EJ, for the EPISTENT Investigators. Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events. Data from the evaluation of glycoprotein IIb/IIIa inhibitor for stenting (EPISTENT) trial. Circulation. 2001;103:1403-9.
16. Valgimigli M, Percoco G, Barbieri D, Ferrari F, Guardigli G, Parrinello G, et al. The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty. The ADVANCE trial. J Am Coll Cardiol. 2004;44:14-9.
17. Kastrati A, Mehilli J, Neumann FJ, Dotzer F, ten Berg J, Bollwein H, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment. The ISAR-REACT 2 randomized trial. JAMA. 2006;295:1531-8.
18. Rasoul S, Ottervanger JP, De Boer MJ, Miedema K, Hoorntje JC, Gosselink M, et al. A comparison of dual vs. triple antiplatelet therapy in patients with non-ST-segment-elevation acute coronary syndrome: results of the ELISA-2 trial. Eur Heart J. 2006;27:1401-7.
19. Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial - phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 1988;11:1-11.
20. Smith SC Jr., Feldman TE, Hirshfeld JW Jr., Jacobs AK, Kern MJ, King SB III, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation. 2006;113:e166-e286.
21. Ruano-Marco M, Fuset-Cabanes MP. Inhibidores de los receptores plaquetarios IIb/IIIa en el SCASEST. Med Intensiva. 2006;4:3-7.